Emerging Drugs and Targets for Alzheimer’s Disease

Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets under the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs.

Beta-Amyloid as target; Chapter 1: The amyloid hypothesis of AD and prospects for therapeutics; Chapter 2: Targeting Alzheimer's ?-Secretase: Genetic and Chemical Modulation; Chapter 3: Cholesterol and AD: the molecules, the targets; Chapter 4: The Bimodal Features of Butyrylcholinesterase in Cholinergic Neurotransmission and Amyloid Suppression; Chapter 5: Scyllo-inositol, a potential therapy for Alzheimer's disease; Chapter 6: Immunotherapeutic strategies toward treatment of AD; Tau protein as target; Chapter 7: Alzheimer Neurofibrillary Degeneration: Pivotal Role and Therapeutic Targets; Chapter 8: Multiple roles of glycogen synthase kinase-3 in AD; Chapter 9: Tau protein kinases inhibitors: from the bench to the clinical trials; Chapter 10: Activating PP2A as a therapeutic intervention strategy in AD; Chapter 11: Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies; Glucose Metabolism as target; Chapter 12: Insulin Insulin Resistance and neurodegeneration: Type 2 versus type 3 diabetes mellitus; Chapter 13: Insulin-like Growth Factor I as a disease-modifying therapy in Alzheimer s disease; Chapter 14: Ketone bodies as a therapeutic for Alzheimer s disease